Clinical trials: IOL
Breast Cancer, Leukemia
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00237627
- Testing
- PS-341, Doxil, Velcade
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cataract
A Prospective Observational Case Series of a Four-ring-haptic Acrylic One-piece IOL
To describe biocompatibility, postoperative results and complications after implantation of the Corneal Quatrix Evolutive (Corneal, Croma, Austria) intraocular lens, a hydrophilic acrylic intraocular lens (IOL) with 4-haptic…
- Trial name
- Qu01 (NCT01244373)
- Where
- Austria
- Volunteers
- 9 people
- Sponsor
- General Hospital Linz
Cataract
EYEFILL® C. -US Viscoelastic Clinical Investigation
The purpose of this multicenter, prospective, randomized clinical study is to determine the safety and effectiveness of the EYEFILL® C.-US Viscoelastic in patients undergoing cataract extraction and intraocular lens (IOL)…
- Trial name
- NCT02024711
- Testing
- EYEFILL® C.-US Viscoelastic, Healon® Viscoelastic (CONTROL)
- Where
- 8 sites in United States
- Volunteers
- 262 people
- Sponsor
- Bausch Health Americas, Inc.
Cataracts
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
The purpose of this study is to compare AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL in both eyes (bilateral implantation) to AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL in the dominant eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal…
- Trial name
- NCT01684007
- Testing
- AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1
- Volunteers
- 112 people
- Sponsor
- Alcon Research
Brain and Central Nervous System Tumors, Lymphoma
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT00621036
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, methotrexate
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Cataract
Level of Agreement of Intraocular Lens Power Measurements Between IOLMaster and Verion
Primary objective of this study is to evaluate the level of agreement of two keratometry modules, the IOLMaster and the Verion Reference Unit, in terms of keratometric values and IOL power calculation.
- Trial name
- NCT03876782
- Testing
- IOLMaster, Verion
- Where
- Greece
- Volunteers
- 54 people
- Sponsor
- Democritus University of Thrace
Lymphoma, Small Intestine Cancer
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma tumors may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future.
- Trial name
- NCT00897923
- Testing
- radionuclide imaging, indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Cataract, Presbyopia Correction
Photopic and Mesopic Multifocal IOL Performance
Modern cataract surgery has become a refractive procedure. Both, multifocal lens implantation and pseudophakic monovision with monofocal IOLs are effective means to address presbyopia correction after cataract surgery.
- Trial name
- MIOLRead (NCT06978556)
- Testing
- No intervention is subject of the study. Only standard pre- and postoperative data will be evaluated.
- Where
- Switzerland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IROC AG
Leukemia, Lymphoma
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002502
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cataract
Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+
Phase 1 will be ambispective, multi-site, single arm study in age-related cataract patients with regular astigmatism, who were bilaterally treated with the LAL+ IOLs Phase 2 will be a prospective, randomized, unmasked…
- Trial name
- NCT06574646
- Testing
- LAL+, Clareon Vivity Toric IOL
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- The Eye Associates
Cataract, Presbyopia
Objective and Subjective Outcomes of a Trifocal IOL in Eyes With Different AL
This prospective cohort study enrolled patients with implantation of a trifocal IOL. Only one eye of each patient was enrolled. Eyes were devided into three groups according the axial length (AL), including the short AL group…
- Conditions
- Cataract, Presbyopia, Lenses, Intraocular, Myopia
- Trial name
- NCT05431868
- Testing
- AT LISA tri 839MP (Carl Zeiss Meditec AG)
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Cataract
AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL
The purpose of this study is to compare the visual outcomes with bilateral implantation of Tecnis MF and ReSTOR IOLs Six months post cataract surgery.
- Trial name
- NCT01278420
- Testing
- Tecnis MF, ReSTOR
- Where
- 6 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Innovative Medical
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Intraocular Lens Dislocation, Aphakia - No Lens Capsule
Horizontal vs Vertical Scleral Tunnels in Flanged IOL Fixation
This study compares the 2-year outcomes of horizontal versus vertical scleral tunnel orientation in flanged intrascleral intraocular lens (IOL) fixation surgery.
- Trial name
- HORVER (NCT07701980)
- Testing
- Flanged Intrascleral IOL Fixation (Yamane Technique)
- Where
- Turkey (Türkiye)
- Volunteers
- 107 people
- Sponsor
- Yuzuncu Yil University
Cataract
EDoF IOLs vs Monofocal IOL
prospective, comparative (3 arms), randomized, multicentric clinical trial
- Trial name
- NCT03172351
- Testing
- EDoF1, Monofocal, EDoF2
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- Carl Zeiss Meditec AG
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Cataracts
AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0] in Japan
The purpose of this study is to evaluate safety and effectiveness of AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] in Japanese cataract patients.
- Trial name
- NCT01605877
- Testing
- AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]
- Where
- 2 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Alcon Research
Cataract, Diabetes
Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties
Modern phacoemulsification techniques have made cataract surgery safe and efficient over the past several decades. Although the phacoemulsification procedure has improved greatly, cataract surgery still involves trauma.
- Conditions
- Cataract, Diabetes, Pseudoexfoliation Syndrome
- Trial name
- POL (NCT01767012)
- Testing
- Polylens EC-HY10-PAL (coated), Polylens EC-Y10-PAL (uncoated)
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
This study will determine the safety and applicability of experimental forms of umbilical cord blood (UCB) transplantation for patients with high risk hematologic malignancies who might benefit from a hematopoietic stem cell…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01652014
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek